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Abstract
Background. Type 1 pseudohypoaldosteronism (PHA1) is
a salt-wasting syndrome caused by mineralocorticoid resis-
tance. Autosomal recessive and dominant hereditary forms
are caused by Epithelial Na Channel andMineralocorticoid
Receptor mutation respectively, while secondary PHA1 is
usually associated with urological problems.
Methods.Ten patients were studied in four French pediatric
units in order to characterize PHA1 spectrum in infants.
Patients were selected by chart review. Genetic, clinical
and biochemistry data were collected and analyzed.
Results. Autosomal recessive PHA1 (n= 3) was diagnosed
at 6 and 7 days of life in three patients presenting with
severe hyperkalaemia and weight loss. After 8 months, 3
and 5 years on follow-up, neurological development and
longitudinal growth was normal with high sodium supple-
mentation.
Autosomal dominant PHA1 (n = 4) was revealed at 15,
19, 22 and 30 days of life because of failure to thrive. At
8 months, 3 and 21 years of age, longitudinal growth was
normal in three patients who were given salt supplemen-
tation; no significant catch-up growth was obtained in the
last patient at 20 months of age.
Secondary PHA1 (n = 3) was diagnosed at 11, 26 days and
5 months of life concomitantly with acute pyelonephritis in
three children with either renal hypoplasia, urinary dupli-
cation or bilateral megaureter. The outcome was favourable
and salt supplementation was discontinued after 3, 11 and
13 months.
Conclusions. PHA1 should be suspected in case of severe
hyperkalemia and weight loss in infants and need careful
management. Pathogenesis of secondary PHA1 is still chal-
lenging and further studies are mandatory to highlight the
link between infection, developing urinary tract and pseu-
dohypoaldosteronism.
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Introduction
Type 1 pseudohypoaldosteronism (PHA1) was first de-
scribed in 1958 by Cheek and Perry [1]. This rare syn-
drome mainly starts during the neonatal period with a wide
spectrum: (i) two genetic forms: a renal form of autosomal
dominant inheritance due to a mutation of the mineralocor-
ticoid receptor (MR) and a severe systemic one of autoso-
mal recessive inheritance due to a mutation of the epithelial
sodium channel (ENaC) gene, and (ii) a secondary form
usually in association with urinary tract malformation and
acute pyelonephritis. We retrospectively analysed 10 cases
in order to describe the clinical and biological course of the
disease.
Patients and methods
We retrospectively investigated 10 patients with a picture
of PHA1 from four paediatric centres, i.e. Lyon Edouard-
Herriot (n = 4), Lyon Debrousse (n = 4), Saint-Etienne
(n = 1) and Noume´a (n = 1) between February 1983 and
June 2005. Patients with adrenal deficiency, salt-wasting
syndrome without relevant hyperkalaemia (K < 6 mmol/l)
and patients without aldosterone dosage were excluded.
Plasma renin and aldosterone concentrations were deter-
mined from available radioimmunoassay kits (Beckman
Immunotech; Marseille, France). For each patient, we col-
lected data for age at diagnosis, clinical data and history,
routine plasma and urine biochemistry at the time of di-
agnosis (sodium, potassium, chloride, bicarbonate, crea-
tinine), ultrasonography, salt supplementation (nadir dose
during the first week after diagnosis) and DNA analysis
when available. Genetic analysis was performed by direct
sequencing of all exons and intronic exon flanking regions
of the genes encoding for the MR (NR3C2) and the three
C© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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Fig. 1. Cutaneous lesions in a female newborn infant with autosomal recessive PHA1: neonatal miliaria crystallina (patient 1).
ENaC subunits (SCNN1A, SCNN1B and SCNN1G) using
the ABI Prism Big Dye Terminator v3.1 Cycle Sequencing
Kit (Applied Biosystems, Foster City, CA, USA) on an ABI
Prism 3700 DNA analyser. Patients with the renal form of
PHA1 were screened for NR3C2 mutations, while those
who were affected by generalized PHA1 were screened for
mutations in SCNN1A, SCNN1B and SCNN1G. Screen-
ing was done according to the clinical picture since NR3C2
mutations are not found in generalized PHA1 andmutations
of the genes encoding for ENaC subunits are not found in
renal PHA1. Screening included the entire NR3C2 gene
(exons and intron–exon junctions) and all the three ENaC
subunit genes. Secondary PHA1 was not analysed.
Results
Patient characteristics are listed in Table 1. All mutations
identified were absent in 210–254 control chromosomes.
Three patients presented with the systemic form of PHA1
Patient 1 was born from consanguineous parents. She pre-
sented with neonatal onset bullous dermatitis (Figure 1a
and b) that evolved towards chronic xerosis and required a
high salt supplementation. Because of long-lasting diges-
tive intolerance, a gastrostomywas performed. At 3 years of
age, she was still fed by gastrostomy and she often suffered
from severe dehydration attacks caused by intercurrent viral
diarrhoea and respiratory distress episodes.
Patient 2 presented with severe dehydration and weight
loss. There was no history of parental consanguinity but
the first child had died at 6 days of life in the absence
of a clear explanation. Further, she mainly suffered from
respiratory symptoms. Her management was based on con-
tinuous sodium chloride administration by a nasogastric
tube. After a 5-year follow-up period, she still experienced
repeated severe dehydration episodes due to diarrhoea and
repeated bronchitis attacks requiring inhaled steroid ther-
apy and physiotherapy.
Patient 3 was born from consanguineous parents. Two
earlier born siblings had died during the first days of life
without diagnosis. She presented with severe weight loss
during the neonatal period and was given salt supplementa-
tion from nasogatric tube. However, she experienced severe
hyperkalaemia (8.9mmol/l) during a gastroenteritis episode
when she was 5 months old. She is now 8 months old and
in good general condition. Three different loss-of-function
mutations were identified in different subunits of the ENaC
(Table 1, Figure 2).
Four additional patients presented with a renal PHA1 and
were found to have different mutations
Patient 4 presented with renal PHA1 as soon as she was
born. She promptly failed to thrive but catch-up growth was
obtained with salt supplementation until 2 years of age. She
is currently 3 years old and her neurological development
and statural growth are normal. The same mutation of the
MR gene was identified in her father in the absence of any
symptoms (Figure 3).
Patient 5 presented with renal PHA1 and improved with
sodium supplementation that was discontinued at 7 years
of age. At 21 years of age, he has normal final height and
intellectual development.
Patient 6 was diagnosed from routine biochemistry prior
to surgery for inguinal hernia, which revealed hypona-
traemia, hyperkalaemia and metabolic acidosis together
with urine salt wasting. The diagnosis of renal PHA1 was
done leading to continuous nasogastric tube feeding since
high salt intake was required. However, his current growth
profile is retarded (−2.5 SD) without significant catch-
up growth. Her mother carries the same MR mutation
(Figure 3); she presented growth delay during childhood
and was still followed for epilepsy and moderate mental
retardation.
Patient 7 presented with failure to thrive. At 8 months
of age, he had a normal longitudinal growth under oral salt
supplementation.
MR mutations were identified in all four patients
(Table 1, Figure 3)
Another three patients exhibited a secondary form of
PHA1
Patient 8 was admitted at 11 days of life because of fail-
ure to thrive and anorexia related to febrile urinary tract
1638 A. Belot et al.
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Fig. 2. ENaCmutations for three patients with the systemic form: view of
the protein subunits, α, β and γ, which assemble as 2 α, 1 β and 1 γ to form
the channel expressed on the cell surface. This channel is widespread in
the organism and is found in kidney, colon, salivar gland, skin and lung.
The three patients presented a nonsense mutation responsible for a stop
codon and a loss of function of the protein.
infection. A diagnosis of secondary PHA1 was made be-
cause of biological results (Table 1) and oral sodium supple-
mentation was given for 11 months since growth velocity
was normal and sodium supplementation was still tapered.
Patient 9 was admitted on the 26th day of life because
of acute pyelonephritis and urinary tract malformation
with poor haemodynamic tolerance. The initial biochem-
ical analyses revealed hyponatraemia, hyperkalaemia and
metabolic acidosis (Table 1). Four hours after admission,
the electrolyte analysis revealed enhanced hyperkalaemia
(from 6.6 to 7.7 mmol/l) as BUN decreased (from 7.1 to
6.3mmol/l) strongly arguing for an ‘MRparalysis’ indepen-
dent of haemodynamic status. A hormonal treatment with
hydrocortisone and fludrocortisone was added to antibiotic
therapy and sodium supplementation was increased from
4 to 6 mmol/kg per day. Under such a treatment, he re-
covered both haemodynamic and biochemical profiles. The
17-OH progesterone, ACTH and cortisol were normal lead-
ing to discontinuation of hormone supplementation. He is
currently 17 months old, in good condition, with a normal
growth velocity so that oral sodium supplementation could
be discontinued at 13 months of age.
Patient 10 had a prenatal diagnosis of bilateral mega-
ureter. At 5.5 months of age, he was admitted for weight
loss, asthenia and vomiting without diarrhoea. The diagno-
sis of PHA1 was suspected from plasma electrolyte mea-
surements and normal renal function (Table 1). After a
short period of time with oral sodium supplementation, he
looked healthy, and salt supplementation could be stopped
at 9 months of age.
MR and ENaC genetic analysis was not performed in this
group of secondary PHA1.
Discussion
PHA is a salt-wasting syndrome due to peripheric resistance
to aldosterone. This may be either a primary (mutation of
Fig. 3. Mutations of the MR gene in four patients with the renal form of
PHA1. View of the gene: exons are represented by black lines and introns
by space in between.
MR or ENaC) or a secondary (infection, uropathy, medi-
cation) phenomenon. In all cases, sodium reabsorption and
potassium excretion are impaired in the principal cell of the
collecting duct. The biological characteristics are hypona-
traemia, hyperkalaemia and acidosis. After having excluded
pseudohyperkalaemia due to haemolysis, the diagnosis may
be challenging. If serum chloride is normal while serum
sodium has decreased and GFR is not impaired, type 4
renal tubular acidosis and acute renal failure can be ruled
out. Then, normal hormone dosage (ACTH, 17-OH proges-
terone, cortisol) allows exclusion of adrenal insufficiency.
Finally, aldosterone and plasma renin dosage leads to the
diagnosis of PHA (high aldosterone and renin concentra-
tions), hypoaldosteronism (high renin, low aldosterone) or
hyporeninaemic hypoaldosteronism (low aldosterone and
renin) [2]. Around 100 patients have been published so far
from both case reports and reviews on mineralocorticoid
resistance [3,4].
This retrospective study is the first one to compare clini-
cal and biological issues, as well as the outcome of the three
forms of PHA. Nevertheless, this study was not able to pro-
vide any estimate of disease incidence. The clinical expe-
rience of paediatric tertiary care hardly suggests a higher
frequency of secondary PHA. In this study, secondary forms
represent 3/10 reports and may be underestimated because
of milder symptoms (K < 6 mmol/l) or absence of routine
aldosterone dosage during the acute phase so that patients
did not fulfil the diagnostic criteria.
Systemic PHA1 is of autosomal recessive inheritance and
is the most severe form of such a salt-wasting syndrome. It
is due to ENaC gene mutation, involving defect in one of
the three subunits and has been associated with 22 known
homozygous or compound heterozygote loss-of-function
mutations [5]. Mice with β or γ subunit mutation die from
dehydration and hyperkalaemia during the firstweeks of life
whereas α subunit knockout leads to death from respiratory
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distress [6–8]. The ENaC subunits are widespread in the
organism (renal collecting duct, respiratory airway, colon
and salivary and sweat glands). In our experience, patients
with systemic PHA1 experienced a rather severe presenta-
tion with two different clinical pictures, i.e. life-threatening
weight loss in patients 2 and 3, and early cutaneous in-
volvement in patient 1 that is a rare feature [9,10]. This
dermatitis is due to high salt concentration in sweat during
the depletive crises causing inflammation and damage in
eccrine structures. Cutaneous lesions are similar to those
appearing in miliaria rubra [9]. The three patients expe-
rienced acute dehydration episodes during gastroenteritis,
and patients 1 and 2 suffered from respiratory recurrent
episodes. These episodes were often secondary to viral in-
fection. This observation underlines the large distribution
of the ENaC subunit and the phenotypic variety according
to the subunit mutation.
In two families (patients 2 and 3), there was a history of
neonatal death during the first week of life. None of our
patients have been diagnosed after the first week of life,
a delay that would favour the issue of fatality. A careful
assessment of body weight and plasma electrolytes should
therefore be recommended in children with a history of
neonatal death in a sibling; in our three patients, the sweat
test has suggested systemic PHA1 and should be proposed
as a simple diagnostic procedure. Salt intakewas rather high
and required tube feeding. During the follow-up, patient 2
presented cystic fibrosis-like symptoms with frequent air-
way obstruction episodes, and patient 1 suffered from re-
peated dehydration attacks due to acute gastroenteritis. A
better knowledge of both genotype and phenotype may im-
prove outcome prediction [11]. The main short-term risk is
death from hyperkalaemia whereas the long-term outcome
depends on life-threatening dehydration episodes and pul-
monary chronic obstruction. There is limited information
on the outcome of systemic PHA with a wide range of
symptoms from isolated growth failure to recurrent lower
respiratory tract infections and dehydration episodes with
life-threatening hyperkalaemia and cardiac arrest [11,12].
PHA cases are associated with mutations leading to the
absence of normal-length α, β or γENaC, while a mild case
has been found to be associated with a missense mutation in
αENaC [5]. Our three observations were particularly severe
and corroborate that the previous data underlining nonsense
mutations are more frequent and more severe than missense
mutation.
Our observation confirms previous recommendations:
high salt intake (Figure 4) and cation exchange resins are
mandatory from the very first days of life towards adulthood
[11,12].
Renal PHA1 is the autosomal dominant form of PHA1
and is due to the allele invalidation in the human MR gene.
The first mutation was described with familial aggregation
[13] and sporadic cases have been further reported [14].
Homozygous mutation of the MR gene has been shown to
be lethal in mice. Both autosomal dominant and sporadic
forms are caused by more than 12 known heterozygous mu-
tations, responsible for MR haploinsufficiency. In our four
cases, the diagnosis was done during the first month of life.
Failure to thrive was the most common initial symptom.
The long-term outcome appeared to be favourable in most
Fig. 4. Nadir salt supplementation in patients with pseudohypoaldostero-
nism (PHA).
cases. In the two older patients, salt intake could be discon-
tinued at 2 (patient 4) and 7 years (patient 5) of age. The
nadir salt intake ranged from 10 to 25 mmol/kg per day, a
dose which did not require any tube feeding (Figure 3). Pa-
tient 6 needed high salt supplementation and did not catch
up growth, maybe because of poor therapeutic compliance.
There was no family history of neonatal death, which
is far different from the paper from Geller et al. [15] who
report on bad outcome in sibling of PHA1. Nevertheless in
this study, parents with renal PHA1 are clinically indistin-
guishable from their unaffected relatives. Affected mother
of patient 6 presented with mental retardation, short size
and epilepsy. These anomalies might be a consequence of
salt depletion episodes during infancy.
No data on the neurodevelopmental outcome of PHA
patients have been published.
Mutations of patients 4 and 6 have been recently pub-
lished [14] whereas others mutations had been described
previously in other patients.
Secondary PHA1 is due to transient aldosterone resis-
tance and is often associated with urinary tract infection
and/or malformation [16–18]. Any kind of congen-
ital urinary tract obstruction (ureterohydronephrosis,
ureterocele, ureteropelvic junction obstruction, posterior
urethral valves) may lead to such PHA1. Other rare causes
of secondary PHA have been observed: systemic lupus
erythematosus, sickle cell nephropathy, acute renal allo-
graft rejection and chronic allograft nephropathy [19]. The
pathophysiology of secondary PHA associated with tubu-
lointerstitial nephritis is still unclear. After 3 months of age,
the prevalence rate of secondary PHA1 decreases dramat-
ically [20]. Since it used to occur in neonates and infants,
tubular immaturity has been advocated. The pathophysi-
ology of tubular resistance may involve cytokine factors
such as TGF-β that is known to decrease MR sensibility
[21] and parenchymal scarring secondary to obstruction.
Clinical and biological findings are comparable to those of
renal PHA1. In our study population, the more precocious
symptoms, the more severe salt wasting, arguing tubular
immaturity. Urine culture and ultrasound examination are
essential to differentiate secondary PHA1 from the genetic
form. However, life-threatening symptoms may occur dur-
ing the first hours of life, such as severe hyperkalaemia
(7.7 mmol/l in patient 9). High salt intake is recommended
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during the acute phase of infection with further progres-
sive tapering. No data are available on the required time
period for such a supplementation (ranging from 3 to 13
months in our hands); it seems that the youngest patients
may require a long-lasting supplementation whereas older
ones have lower salt requirements. Genetic analysis was not
performed in the secondary forms because of their transient
well-known outcome. Nevertheless, genotype investigation
in the presence of secondary PHA may highlight MR or
ENaC polymorphism and therefore help in understanding
the pathophysiology of this disease.
No patient presentedwith hydramnios in our series which
is different from previous description [22]. We have no ex-
planation for this difference; all the pregnancies but one
underwent serial systematic sonography. Prenatal polyuria
might not be a constant feature. In all patients, the diag-
nosis came from routine blood electrolyte assessment [2]
that may be sometimes completed by ACTH, cortisol, al-
dosterone and plasma renin concentration. Urinalysis and
renal ultrasonography were always required in order to al-
low early recognition of secondary PHA1. An early on-
set of symptoms together with high aldosterone level and
salt intake exceeding 30 mmol/kg per day strongly argues
for systemic PHA1 (Figure 4, Table 1) but the severity of
dehydration and hyperkalaemia is not pathognomonic of
systemic PHA1. The long-term prognosis is rather good
for renal and secondary PHA1 but it may be impaired in
patients with the systemic form.
Conclusion
PHA1 has a wide clinical and pathophysiological spectrum.
The most common clinical characteristics include failure
to thrive and dehydration, and the diagnosis is based on
plasma electrolyte assessment. Molecular biology of renal
tubular principal cell has clarified the mechanism of ge-
netic PHA1 whereas secondary PHA1 remains misunder-
stood. Other intracytoplasmic proteins that regulate ENaC
activity (Nedd4, Small-G protein K, CAP1, CFTR) have
been recently identified and could be involved [6,23]. The
study of EnaC andMR polymorphisms in secondary PHA1
carriers is promising.
Conflict of interest statement. None declared.
References
1. Cheek DB, Perry JW. A salt wasting syndrome in infancy. Arch Dis
Child 1958; 33: 252–256
2. Giapros VI, Tsatoulis AA, Drougia EA et al. Rare causes of acute
hyperkalemia in the 1st week of life. Pediatr Nephrol 2004; 19: 1046–
1049
3. Arai K, Chrousos GP. Syndromes of glucocorticoid and mineralocor-
ticoid resistance. Steroids 1995; 60: 173–179
4. Zennaro MC, Lombe`s M. Mineralocorticoid resistance. Trends En-
docrinol Metab 2004; 15: 264–270
5. Edelheit O et al. Novel mutations in epithelial sodium channel (ENaC)
subunit genes and phenotypic expression of multisystem pseudohy-
poaldosteronism. Clin Endocrinol (Oxf) 2005; 62: 547–553
6. Chang SS, Grunder S, Hanukoglu A et al. Mutations in subunits of
the epithelial sodium channel cause salt wasting with hyperkalaemic
acidosis, pseudohypoaldosteronisme type 1.NatGenet 1996; 12: 248–
253
7. Barker PM, Nguyen MS, Gatzy JT et al. Role of γENaC subunit in
liquid clearance and electrolyte balance in newbornmice. J Clin Invest
1998; 102: 1634–1640
8. McDonald F, YangB,Hrstka RF et al. Disruption of the epithelial Na+
channel in mice: hyperkalemia and neonatal death associated with a
pseudohypoaldosteronism phenotype. Proc Natl Acad Sci 1999; 96:
1727–1731
9. Martin JM, Calduch L, Monteagudo C et al. Clinico-pathological
analysis of the cutaneous lesions of a patient with type I pseudohy-
poaldosteronism. J Eur Acad Dermatol Venereol 2005; 19: 377–379
10. Urbatsch A, Paller AS. Pustular miliaria rubra: a specific cutaneous
finding of type I pseudohypoaldosteronism. Pediatr Dermatol 2002;
19: 317–319
11. Edelheit O, Hanukoglu I, Gizewska M et al. Novel mutations in ep-
ithelial sodium channel (ENaC) subunit genes and phenotypic expres-
sion of multisystem pseudohypoaldosteronism.Clin Endocrinol (Oxf)
2005; 62: 547–553
12. Hogg RJ,Marks JF,Marver D et al. Long term observation in a patient
with pseudohypoaldosteronism. Pediatr Nephrol 1991; 5: 205–210
13. Geller DS, Rodriguez-Soriano J, Vallo Boado A et al. Mutations in
the mineralocorticoid receptor gene cause autosomal dominant pseu-
dohypoaldosteronism type 1. Nat Genet 1998; 19: 279–281
14. Pujo L, Fagart J, Gary F et al. Mineralocorticoid receptor mutations
are the principal cause of renal type 1 pseudohypoaldosteronism.Hum
Mutat 2007; 28: 33–40
15. Geller DS, Zhang J, Zennaro MC et al. Autosomal dominant pseudo-
hypoaldosteronism type 1: mechanisms, evidence for neonatal lethal-
ity, and phenotypic expression in adults. J Am Soc Nephrol 2006; 17:
1429–1436
16. Trentesaux AS, Roussel B, Bendarek N et al. Transient neonatal pseu-
dohypoaldosteronism. Arch Pediatr 1998; 5: 1171–1172
17. Rodriguez-Soriano J. Tubular disorders of electrolyte regulation.Pedi-
atric Nephrology,Vol. 31C, 3rd edn. Baltimore:Williams andWilkins,
1994, 631–632
18. Husted RF, Matsushita K, Stokes JB. Induction of resistance to min-
eralocorticoid hormone in cultured inner medullary collecting duct
cells by TGF-b1. Am J Physiol 1994; 267: 767–775
19. Proctor, G. and Linas S. Type 2 pseudohypoaldosteronism: new in-
sights into renal potassium, sodium, and chloride handling. Am J
Kidney Dis 2006; 48: 674–693
20. Melzi ML, Guez S, Sersale G et al. Acute pyelonephritis as a cause
of hyponatremia/hyperkalemia in young infants with urinary tract
malformation. Pediatr Infect Dis J 1995; 14: 56–59
21. Watanabe T. Reversible secondary pseudohypoaldosteronism.Pediatr
Nephrol 2003; 18: 486
22. Greenberg D, Abramson O, Phillip M. Fetal pseudohypoaldostero-
nism: another cause of hydramnios. Acta Paediatr 1995; 84: 582–584
23. GormleyK,DongY, SagnellaGA.Regulation of the epithelial sodium
channel by accessory proteins. Biochem J 2003; 371: 1–14
Received for publication: 2.8.06
Accepted in revised form: 14.11.07
